Cambridge Nutritional Sciences (FRA:RVKA) Payments of Debt: €0.00 Mil (TTM As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Cambridge Nutritional Sciences Payments of Debt?

Cambridge Nutritional Sciences FRA:RVKA -50.00% Payments of Debt is €0.00 Mil as of Sep. 2025. The stock has 3 warning signs investors should review.

Cambridge Nutritional Sciences's Payments of Debt for the six months ended in Sep. 2025 was €0.00 Mil.

Cambridge Nutritional Sciences's Payments of Debt for the trailing twelve months (TTM) ended in Sep. 2025 was €0.00 Mil.

Cambridge Nutritional Sciences Payments of Debt Related Terms

Cambridge Nutritional Sciences Payments of Debt Historical Data

* Premium members only.

The historical data trend for Cambridge Nutritional Sciences's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cambridge Nutritional Sciences Payments of Debt Chart

Cambridge Nutritional Sciences Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Payments of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.66 0.00 0.00 0.00 0.00

Cambridge Nutritional Sciences Semi-Annual Data
Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Cambridge Nutritional Sciences Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Sep. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of €0.00 Mil mean?
Cambridge Nutritional Sciences (FRA:RVKA) has a Payments of Debt of €0.00 Mil as of Sep. 2025. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Cambridge Nutritional Sciences and its competitors.
Is Cambridge Nutritional Sciences' Payments of Debt too high?
Cambridge Nutritional Sciences' current Payments of Debt is €0.00 Mil.
How does Cambridge Nutritional Sciences' Payments of Debt compare to ISRG and BDX?
Cambridge Nutritional Sciences' Payments of Debt of €0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Medical Devices & Instruments company?
A good Payments of Debt depends on the Medical Devices & Instruments industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Cambridge Nutritional Sciences and its competitors. Cambridge Nutritional Sciences's current Payments of Debt is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cambridge Nutritional Sciences stock overvalued right now?
Cambridge Nutritional Sciences (FRA:RVKA) has a current Payments of Debt of €0.00 Mil. The stock's GF Value™ is €0.02, compared to a current price of €0.01 — trading 30% below its estimated fair value. The current Payments of Debt is €0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For Cambridge Nutritional Sciences (FRA:RVKA), the current Payments of Debt is €0.00 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cambridge Nutritional Sciences Business Description

Other Exchanges CNSL:UK
Address One Fleet Place, London, GBR, EC4M 7WS
Cambridge Nutritional Sciences PLC is a medical diagnostics company specializing in the development, manufacture, and distribution of food sensitivity test kits. Its product portfolio includes tests designed to detect immune reactions to various foods, helping healthcare professionals and patients identify dietary and lifestyle changes to improve long-term health and wellbeing. The company operates in the United Kingdom and serves the customer base across various countries through laboratories and healthcare providers. It generates revenue by selling diagnostic kits and providing clinical analysis services centered on food sensitivity and gut health. The group has two reportable segments: Health and Nutrition; and Corporate. The Health and Nutrition segment generates majority revenue.